Suppr超能文献

代谢型谷氨酸受体作为镇痛靶点:拮抗、激活和变构调节。

Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.

机构信息

Washington University Pain Center, Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

出版信息

Curr Pharm Biotechnol. 2011 Oct;12(10):1681-8. doi: 10.2174/138920111798357438.

Abstract

The metabotropic glutamate receptors (mGluRs) are expressed pre- and post-synaptically throughout the nervous system where they serve as modulators of synaptic transmission and neuronal excitability. Activation of mGluRs can be pro- or anti-nociceptive, depending on their anatomic location and the signaling cascades to which they couple. Antagonists of Group I mGluRs and agonists of Group II and III mGluRs have shown therapeutic promise in animal pain models. This article reviews the potential therapeutic utility of several agents that act predominantly via mGluRs, specifically focusing on their analgesic efficacy and discussing possible off-target effects. Glutamate, the primary excitatory neurotransmitter in the vertebrate nervous system, mediates its effects via activation of two main classes of receptors: ligand-gated ion channels known as ionotropic receptors and G-protein coupled metabotropic receptors. Antagonists of ionotropic glutamate receptors, such as ketamine, have robust analgesic properties; however, their analgesic utility is limited to monitored clinical settings due to the potential for psychomimetic effects.

摘要

代谢型谷氨酸受体(mGluRs)在整个神经系统中均有表达,无论是在突触前还是突触后,它们都可以作为突触传递和神经元兴奋性的调节剂。mGluRs 的激活可以是痛觉过敏或镇痛,这取决于它们的解剖位置和与之偶联的信号级联。I 组 mGluRs 的拮抗剂和 II 组和 III 组 mGluRs 的激动剂在动物疼痛模型中显示出治疗潜力。本文综述了几种主要通过 mGluRs 发挥作用的药物的潜在治疗用途,特别关注它们的镇痛效果,并讨论可能的脱靶效应。谷氨酸是脊椎动物神经系统中的主要兴奋性神经递质,通过激活两种主要类型的受体来介导其作用:配体门控离子通道,称为离子型受体和 G 蛋白偶联代谢型受体。离子型谷氨酸受体拮抗剂,如氯胺酮,具有很强的镇痛作用;然而,由于潜在的拟精神病作用,它们的镇痛用途仅限于监测临床环境。

相似文献

1
Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation.
Curr Pharm Biotechnol. 2011 Oct;12(10):1681-8. doi: 10.2174/138920111798357438.
2
Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond.
Eur J Neurosci. 2014 Feb;39(3):444-54. doi: 10.1111/ejn.12398.
3
Metabotropic receptors for glutamate and GABA in pain.
Brain Res Rev. 2009 Apr;60(1):43-56. doi: 10.1016/j.brainresrev.2008.12.007. Epub 2008 Dec 25.
4
Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.
Front Mol Neurosci. 2018 Oct 9;11:383. doi: 10.3389/fnmol.2018.00383. eCollection 2018.
5
Nociception modulation by supraspinal group III metabotropic glutamate receptors.
J Neurochem. 2017 May;141(4):507-519. doi: 10.1111/jnc.13725. Epub 2017 Feb 22.
6
The glutamatergic system as a target for neuropathic pain relief.
Exp Physiol. 2013 Feb;98(2):372-84. doi: 10.1113/expphysiol.2012.069922. Epub 2012 Sep 21.
7
8
Metabotropic glutamate receptors and neurodegenerative diseases.
Pharmacol Res. 2017 Jan;115:179-191. doi: 10.1016/j.phrs.2016.11.013. Epub 2016 Nov 19.
9
Modulation of Chronic Pain by Metabotropic Glutamate Receptors.
Adv Pharmacol. 2016;75:63-89. doi: 10.1016/bs.apha.2015.11.001. Epub 2016 Jan 6.
10
Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy.
Epilepsy Res. 2006 Sep;71(1):1-22. doi: 10.1016/j.eplepsyres.2006.05.012. Epub 2006 Jun 19.

引用本文的文献

1
Structural insights into the function, dysfunction and modulation of Kv3 channels.
Neuropharmacology. 2025 Sep 1;275:110483. doi: 10.1016/j.neuropharm.2025.110483. Epub 2025 Apr 25.
2
Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.
Curr Neuropharmacol. 2025;23(3):276-294. doi: 10.2174/1570159X23666241011163035.
4
Recent Advances in the Modulation of Pain by the Metabotropic Glutamate Receptors.
Cells. 2022 Aug 21;11(16):2608. doi: 10.3390/cells11162608.
6
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update.
Int J Mol Sci. 2021 Apr 9;22(8):3891. doi: 10.3390/ijms22083891.
9
Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers.
Mol Pain. 2019 Jan-Dec;15:1744806918819944. doi: 10.1177/1744806918819944. Epub 2018 Nov 29.
10
Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.
Front Mol Neurosci. 2018 Oct 9;11:383. doi: 10.3389/fnmol.2018.00383. eCollection 2018.

本文引用的文献

1
Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior.
J Neurosci. 2010 Jun 16;30(24):8203-13. doi: 10.1523/JNEUROSCI.1216-10.2010.
2
Reactive oxygen species are involved in group I mGluR-mediated facilitation of nociceptive processing in amygdala neurons.
J Neurophysiol. 2010 Jul;104(1):218-29. doi: 10.1152/jn.00223.2010. Epub 2010 May 12.
3
Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?
Expert Opin Investig Drugs. 2010 Apr;19(4):555-61. doi: 10.1517/13543781003691832.
4
Unmasking the tonic-aversive state in neuropathic pain.
Nat Neurosci. 2009 Nov;12(11):1364-6. doi: 10.1038/nn.2407. Epub 2009 Sep 27.
6
Hemispheric lateralization of pain processing by amygdala neurons.
J Neurophysiol. 2009 Oct;102(4):2253-64. doi: 10.1152/jn.00166.2009. Epub 2009 Jul 22.
9
The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning.
Neuropharmacology. 2009 Aug;57(2):97-108. doi: 10.1016/j.neuropharm.2009.04.011. Epub 2009 May 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验